While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
According to CDC researchers, cases of tularemia in the U.S. increased by nearly 60% from 2011 to 2022 compared with the ...
According to a Reuters article, pharma companies launched new US drugs at prices 35% higher in 2023 compared to those ...
Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...
Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according to a research letter.
10h
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
Decoy's proprietary IMP3ACT peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding and ...
Investor's Business Daily on MSN10h
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?Moderna stock took a beating in January after the company slashed its outlook for 2024 and 2025 and missed the mark in a CMV ...
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback